Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
REGULATORY
Counterfeit Harvoni Discovered in Nara Pharmacy, MHLW Investigating Route of Entry into Distribution
Counterfeits of Gilead Sciences’s hepatitis C treatment Harvoni Combination Tablets (ledipasvir + sofosbuvir) have been discovered at a pharmacy chain in Nara Prefecture, the Ministry of Health, Labor and Welfare (MHLW) revealed on January 17. The MHLW issued a notification…
To read the full story
Related Article
- Wholesale Dealer President Deeply Sorry for Letting Fake Harvoni into Supply Chain
March 24, 2017
- 2 Kansai Medico Pharmacy Outlets Ordered to Suspend Biz
March 17, 2017
- 3 Kansai Medico Pharmacies Slapped with Biz Improvement Order over Fake Harvoni
March 7, 2017
- MHLW Mulls Administrative Penalties, Tighter Regulations after Counterfeit Harvoni Case
February 14, 2017
- MHLW Wraps Up Probe into Fake Harvoni after Distribution Routes “Most Likely” Identified
February 2, 2017
- MHLW Pins Down Distribution Routes for Harvoni Counterfeits; Composition of Fake Pills Identified
February 1, 2017
- MHLW Warns Against Purchasing Harvoni in Unpackaged Bottles
January 26, 2017
- Kansai Medico Used Non-Official Harvoni Dealer for Cheaper Price
January 25, 2017
- Kansai Medico Issues Apology over Harvoni Counterfeits
January 24, 2017
- Counterfeit Harvoni Found in Tokyo Too, Route Identified for a Nara Bottle
January 24, 2017
- MHLW Asks Pref. Govt to Conduct On-Site Inspections for Pharmacies, Wholesalers: Minister
January 23, 2017
- Counterfeit Harvoni Likely Entered Distribution before Reaching Pharmacies: MHLW Official
January 23, 2017
- NPhA Instructing Member Pharmacies on Careful Drug Purchases after Fake Harvoni Issue: Chief
January 20, 2017
- We Must Redouble Efforts for Proper Drug Distribution, Pharmacist Group Says on Fake Harvoni Issue
January 19, 2017
- Gilead Japan to Switch Sovaldi, Harvoni Bottles to Blister Packs
January 19, 2017
- Gilead Asks Pharmacists to Open Harvoni Bottles in Front of Patients after Fake Drug Found
January 18, 2017
REGULATORY
- Japan Likely to Extend “Catch-Up” HPV Vaccination Program
November 26, 2024
- As 2025 Budgeting Nears, “No” to Off-Year Revisions Arises from LDP Too
November 26, 2024
- Japan Gets Down to the Business of Solving Drug Loss, New Scheme Begins with 78 Meds
November 26, 2024
- MHLW Proposes Upping Copay Limits in High-Cost Medical Expense Scheme
November 25, 2024
- Japan’s New Economic Package Covers Pharma-Related Steps, but Not Repeal of Off-Year Revisions
November 25, 2024
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…